For those ready to switch
If you smoke, or use gutka, khaini or other toxic SLT — this is what the evidence says about switching
You would not be the first. An estimated 200 million people worldwidehave already replaced combustible tobacco or toxic smokeless tobacco with a lower-risk nicotine product — vaping, heated tobacco, nicotine pouches or snus — according to the2026 Global State of Tobacco Harm Reduction report. This page sets out what the evidence says about whether switching works, not how to obtain any product — see the legal note below for why.
Does switching actually work?
Cochrane, 2025 (living review)
Per 100 smokers trying to quit, about 8–10 succeed with nicotine e-cigarettes, versus 6 with nicotine replacement therapy (gums, patches) and 4 with no support at all — the best-certainty head-to-head evidence available, and it favours e-cigarettes over NRT.
Read the review →JAMA / SRNT consensus, 2026
A statement from the Society for Research on Nicotine and Tobacco's Treatment Research Network recommends doctors discuss nicotine e-cigarettes as a cessation option with adult smokers, alongside other evidence-based treatments — the first such US clinical guidance of its kind.
Read the consensus statement →India-specific: 3,000-vaper survey, 2020
The largest India-specific study found: 71.3% of surveyed smokers quit (30.0%) or reduced (41.3%) smoking with e-cigarettes; similar patterns held for smokeless tobacco users. A convenience sample of self-selected vapers, not a population-representative one — but the largest evidence India has of its kind.
Read the study →ASH UK, ongoing tracking
An estimated 3.3 million UK adults have quit smoking using a vape, and e-cigarettes are used in roughly half of successful quit attempts recorded in the UK's national tracking survey.
Read the ASH release →Sweden — the population-scale precedent
Sweden's decades-long shift from smoking to snus produced the lowest daily smoking rate in Europe (~5%), alongside 44% lower tobacco-attributable mortality than the EU average. Swedish snus is a different, quality-controlled product from Indian khaini/gutkha/zarda — the lesson is that reduced-risk smokeless substitution works at population scale, not that Indian SLT products are already safe as-is.
Read the analysis →US FDA, modified-risk authorisations
After scientific review, the FDA has authorised specific reduced-exposure and modified-risk marketing claims for e-cigarette, heated-tobacco and nicotine-pouch product categories found to measurably lower exposure to harmful chemicals compared with cigarettes.
See FDA's orders →What the evidence says matters, if you switch
- Switch completely, not partially. Continuing to smoke alongside a lower-risk product ("dual use") keeps most of the risk of smoking. The health bodies above are consistent on this: the benefit comes from replacing combustible tobacco, not adding to it.
- Nicotine itself is not the main harm. The overwhelming evidence, summarised by the UK's Royal College of Physicians and others, is that it is the burning of tobacco — the tar and thousands of combustion byproducts — that causes most smoking-related disease, not the nicotine.
- Behavioural support helps, whichever method you use. Every body cited on this page that studied it found combining a lower-risk product with some form of counselling or structured support improved quit outcomes further.
- "Less harmful" is not "harmless." Every major body cited here is explicit about this. The comparison that matters for an existing smoker or SLT user is against continuing to smoke or chew — not against using nothing at all.
Independent resources, for further reading
These are independent, non-AVI resources that compile THR evidence in more depth. Several reflect the regulatory context of countries where these products are legal — not India's, where the law is set out below.
- Safer Nicotine Wiki — a community-maintained encyclopedia indexing primary THR evidence and sourcing.
- Global State of Tobacco Harm Reduction (GSTHR) — country-by-country data on safer nicotine product use and regulation, including an India profile.
- Clive Bates' THR Q&A — a roughly 60-question framework across relative risk, quitting efficacy, youth uptake, regulation and more.
- Action on Smoking and Health (ASH UK) — ongoing tracking survey data and evidence summaries.
- Cochrane Library — the living systematic review itself, periodically updated.
- Global Action to End Smoking — a research database on THR and cessation. Funded by a multi-year pledge from Philip Morris International (2018–2023, as the Foundation for a Smoke-Free World); disclosed here so you can weigh the source yourself.
- Arielle Selya's Substack — a researcher's critique of methodological flaws in nicotine/tobacco studies. Selya also consults for Pinney Associates, which advises nicotine and tobacco companies including JUUL.
The legal reality in India, today
E-cigarettes are banned in India under PECA, 2019, including possession. Nicotine pouches and snus have no lawful sale pathway either, via a different mechanism. This page does not sell, advertise, or facilitate access to any nicotine product, and provides no purchasing guidance — nothing here should be read as encouraging violation of PECA or any other applicable law. AVI's position is that adult smokers and SLT users should have legal, regulated access to the lower-risk alternatives this page's evidence describes — our advocacy is directed at changing the law through evidence and public debate, not at circumventing it in the meantime.
Read the full legal position →